CaroGen Corporation utilizes its proprietary AVIDIO platform, an RNA-based artificial virus technology, to develop recombinant protein nanoparticle vaccines targeting infectious diseases and immuno-oncology. The company aims to provide effective immunotherapies for chronic conditions such as hepatitis B and ovarian cancer, addressing the need for advanced treatment options in these areas.
Funding
$6.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
USFounders
Product
Problem
Current treatments for chronic infections like hepatitis B and cancers such as ovarian cancer often lack the ability to generate a robust and targeted immune response, leading to limited long-term efficacy and potential for recurrence. Traditional vaccine and immunotherapy approaches may struggle to effectively deliver multiple antigens or immunomodulatory signals necessary to overcome immune tolerance or suppression within the tumor microenvironment.
Solution
CaroGen Corporation is developing a novel class of recombinant protein nanoparticle vaccines and immunotherapies based on its proprietary AVIDIO platform, an RNA-based artificial virus technology. The AVIDIO platform is designed to deliver multiple transgenes, encoding antigens and immune-stimulating factors, to elicit broad spectrum of immune responses. CaroGen's lead candidates, CARG-201 and CARG-2020, are in late-stage preclinical development, targeting chronic hepatitis B and recurrent ovarian cancer, respectively. The AVIDIO platform's capacity to deliver multiple transgenes allows for a multifaceted approach to modulating the immune system, potentially leading to more effective and durable therapeutic outcomes. By stimulating both innate and adaptive immunity, CaroGen aims to restore immune surveillance and overcome mechanisms of immune evasion employed by chronic infections and tumors.
Target Audience
The primary target audience includes patients suffering from chronic infectious diseases like hepatitis B and cancers such as recurrent ovarian cancer, as well as clinicians and researchers seeking more effective immunotherapeutic interventions.
Features
- AVIDIO platform: RNA-based artificial virus technology for targeted delivery of multiple transgenes
- Recombinant protein nanoparticle vaccines designed to elicit broad spectrum of immune responses
- CARG-201: Immunotherapy candidate for chronic hepatitis B, currently in late-stage preclinical development
- CARG-2020: Immunotherapy candidate for recurrent ovarian cancer, currently in late-stage preclinical development
- Capacity to deliver multiple transgenes encoding antigens and immune-stimulating factors
- Designed to stimulate both innate and adaptive immunity
- Broad and expanding patent portfolio covering composition of matter and methods of use